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Introduction {#sec001}
============

Parkinson\'s disease (PD) is a slowly progressive, irreversible neurodegenerative disease of the central nervous system that affects about 1% of people aged 65 years and over worldwide \[[@pone.0203473.ref001]\]. Globally, the incidence of PD ranges from 10--18 per 100,000 person-years \[[@pone.0203473.ref001]\]. Aging populations and rising life expectancies worldwide have led to the prediction that the number of people aged over 50 years with PD in Western Europe's five most and the world's 10 most populous nations will double from between 4.1 and 4.6 million in 2005 to between 8.7 and 9.3 million by 2030 \[[@pone.0203473.ref002]\]. In 2016, 13.20% of the Taiwanese population was aged 65 years and over \[[@pone.0203473.ref003]\], and Taiwan's census data reveal average life expectancies of 76.81 years for males and 83.42 years for females \[[@pone.0203473.ref004]\]. As Taiwan progressively steps into an 'aged' country, PD will very soon become a great challenge for public health in Taiwan.

Initially, PD patients exhibit rest tremor, muscular rigidity, gait impairment and postural instability that is not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction. Specific non-motor features become obvious as the disease progresses (olfactory dysfunction, cognitive impairment, psychiatric symptoms, sleep disorders, autonomic dysfunction, pain, and fatigue), resulting in clinically significant disability \[[@pone.0203473.ref001]\]. The shift from impairment to disability in PD occurs within 3 to 7 years after diagnosis \[[@pone.0203473.ref005]\]. Patients with late-stage disease tend to experience axial motor symptoms such as postural instability with frequent falls and freezing of gait \[[@pone.0203473.ref001]\]. The process becomes risk of developing aspiration pneumonia. Psychological problems often accompany including anxiety, depression, insomnia, cognitive problems and hallucinations \[[@pone.0203473.ref006]\]. Long-term complications of dopaminergic therapies for PD are characterized by fluctuations, dyskinesia and psychosis, all of which contribute to disability \[[@pone.0203473.ref001]\]. In late-stage disease, levodopa-resistant symptoms contribute to disability and markedly increase the risk of all-cause mortality \[[@pone.0203473.ref001]\].

Clinical evidence suggests that the progression of PD is aggravated by vascular risk factors including diabetes \[[@pone.0203473.ref007]\] and hypertension \[[@pone.0203473.ref008]\]. Otherwise PD twice the general population to develop cardiovascular disease and have a 50% greater chance of dying from it \[[@pone.0203473.ref009]\]. Some researchers have found that PD is linked to an increased risk of stroke and a higher risk of stroke-related mortality \[[@pone.0203473.ref010], [@pone.0203473.ref011]\]. However a number of studies have demonstrated that traditional Chinese medicine (TCM) \[[@pone.0203473.ref012]--[@pone.0203473.ref015]\], acupuncture \[[@pone.0203473.ref016], [@pone.0203473.ref017]\], and Tai Chi \[[@pone.0203473.ref018]\] improve impairments associated with neurologic sequelae. Since none of the currently available treatments for PD are specifically designed to prevent stroke, this therapeutic area presents an important unmet need. The purpose of this study was to investigate the prophylactic benefit of TCM in the prevention of stroke among patients with PD.

Materials and methods {#sec002}
=====================

Data source {#sec003}
-----------

Taiwan's single-payer National Health Insurance (NHI) program delivers universal health coverage to its residents \[[@pone.0203473.ref019]\]. De-identified claims data from the NHI Research Database provided the study participants' details on gender, date of birth, clinical visits and hospitalizations, medicines prescribed and their dosages (including Chinese herb products), medical expenditure, as well as the disease diagnosis classified according to International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Our study was approved by the Ethics Review Board of China Medical University (CMUH104-REC2-115).

Study subjects {#sec004}
--------------

Study subjects were selected from the Longitudinal Health Insurance Database (LHID2010) ([Fig 1](#pone.0203473.g001){ref-type="fig"}). The LHID2010 contains registration and claims data of 1,000,000 NHI beneficiaries randomly sampled from all those enrolled between Jan. 1, 2010 and Dec. 31, 2010. Gender distribution does not differ significantly between patients in the LHID2010 and the original National Health Insurance Research Database (NHIRD). We identified all individuals aged older than 18 years with newly-diagnosed PD (ICD-9-CM code 332.x) who made at least two visits seeking clinical medical care with diagnosis to PD in the entire study period from 1997 to 2011. PD patients who had at least one Chinese herbal medicine (CHM) prescription were defined as CHM users, whereas PD patients who had no such details were defined as non-CHM users. We excluded CHM users who received CHM treatment before the diagnosed date of PD and who received acupuncture intervention. The index date was defined as the first date that PD patients started to receive CHM treatment. Immortal time was defined as the period from the initial diagnostic date of PD to the index date. We then randomly selected non-CHM users as the comparison cohort (ratio 1:1), which were matched by age (in 5-year increments), gender, index year of CHM prescription (initial CHM prescription following the new PD diagnosis date), and initial year of PD diagnosis.

![Flowchart for the patient-selection from the Longitudinal Health Insurance Database in Taiwan.](pone.0203473.g001){#pone.0203473.g001}

Measurement outcomes, comorbidities, and medication use {#sec005}
-------------------------------------------------------

The primary outcome was the occurrence of stroke. Patients with stroke were identified using ICD-9-CM codes 430 to 438 with at least 2 ambulatory claims or at least 1 claim for inpatient care. Patients who diagnosed with stroke before the index date of CHM prescription were excluded. All patients were traced from the index date of CHM prescription to the date of stroke diagnosis, withdrawal from the NHI program, or to the end of 2013. The following comorbidities identified before the index date were considered to be potential confounding factors for PD: hypertension (ICD-9-CM code 401 to 405), hyperlipidemia (ICD-9-CM code 272), and diabetes mellitus (DM, ICD-9-CM code 250). The following comorbidities identified before the index date were also considered to be potential confounding factors for stroke: artial fibrillation (AF, ICD-9-CM code 427.31), transient ischemic attack (TIA, ICD-9-CM code 435.9), congestive heart failure (CHF, ICD-9-CM code 428.0), and peripheral vascular disease (PVD, ICD-9-CM code 443.9). Our analysis included the following anti-parkinsonian medications: Pramipexole, Ropinirole, Rotigotine, Trihexyphenidyl, Levodopa, Entacapone, Rasagiline, Aspirin, and Plavix.

Statistical analysis {#sec006}
--------------------

Baseline demographic variables and potential risk factors in the CHM group and non-CHM group were analyzed using Chi-Square and t-test calculations for categorical variables and continuous variables, respectively. The crude hazard ratios (HR) and 95% confidence intervals (CI) of stroke in both cohort groups were estimated by time-independent Cox proportional hazard regression models; incidence rates of stroke were calculated after stratifying each variable. Kaplan-Meier analysis of the cumulative incidence of stroke was performed for both groups. All analyses were carried out using SAS statistical software (version 9.4 for Windows; SAS Institute, Inc., Cary, NC, USA). Statistical significance was determined with P \<0.05.

Results {#sec007}
=======

Eligible study participants included 1,882 patients with PD; 853 had used CHM and 1,029 had not. After matching the cohorts, a total of 580 patients were eligible for the study (CHM users: N = 290; non-CHM users: N = 290). The mean age (standard deviation) was 70.64 (±11.58) years in the CHM users and 70.74 (±11.59) years in the non-CHM users. Study subjects were predominantly male (55.17%) and older than 70 years (65.17%). Compared with non-CHM users, a significantly higher proportion of CHM users had hyperlipidemia (CHM user: 34.14%, non-CHM user: 21.03%; P \<0.001) and anti-parkinsonian drugs prescription (CHM users: 87.24%, non-CHM user: 73.45; P\<0.001). No significant difference has been found in the proportion of stroke-related risk factors between CHM and non-CHM users. Mean follow-up durations were 3.79 years for the CHM users and 2.01 years for the non-CHM users. ([Table 1](#pone.0203473.t001){ref-type="table"})

10.1371/journal.pone.0203473.t001

###### Demographic characteristics of the patients with Parkinson\'s disease in Taiwan between 1997--2011.

![](pone.0203473.t001){#pone.0203473.t001g}

  Variable                                                                                                     Without CHM    With CHM       p value                                                  
  ------------------------------------------------------------------------------------------------------------ -------------- -------------- ------------------------------------------------ ------- -----------------------------------------------
  **Sex**                                                                                                                                                                                             0.99[^\#^](#t001fn003){ref-type="table-fn"}
      Female                                                                                                   130            44.83          130                                              44.83   
      Male                                                                                                     160            55.17          160                                              55.17   
  **Age at baseline, years**                                                                                                                                                                          0.99[^\#^](#t001fn003){ref-type="table-fn"}
      18--59                                                                                                   36             12.41          36                                               12.41   
      60--69                                                                                                   65             22.41          65                                               22.41   
      Older than 70 years                                                                                      189            65.17          189                                              65.17   
      Mean(SD)                                                                                                 70.74(11.59)   70.64(11.58)   0.9251[^‡^](#t001fn002){ref-type="table-fn"}             
  **Baseline comorbidities**                                                                                                                                                                          
      Hypertension                                                                                             175            60.34          173                                              59.66   0.8654[^\#^](#t001fn003){ref-type="table-fn"}
      Hyperlipidemia                                                                                           61             21.03          99                                               34.14   0.0004[^\#^](#t001fn003){ref-type="table-fn"}
      DM                                                                                                       79             27.24          93                                               32.07   0.2031[^\#^](#t001fn003){ref-type="table-fn"}
      AF                                                                                                       7              2.41           5                                                1.72    0.5596[^\#^](#t001fn003){ref-type="table-fn"}
      TIA                                                                                                      0              0              0                                                0       \-
      CHF                                                                                                      20             6.9            14                                               4.83    0.2889[^\#^](#t001fn003){ref-type="table-fn"}
      PVD                                                                                                      3              1.03           6                                                2.07    0.5044[†](#t001fn004){ref-type="table-fn"}
  [^§^](#t001fn005){ref-type="table-fn"}**Drug used (after initial diagnosis date of Parkinson\'s disease)**                                                                                          0.0919[^\#^](#t001fn003){ref-type="table-fn"}
      No                                                                                                       77             26.55          37                                               12.76   
      Yes                                                                                                      213            73.45          253                                              87.24   
  **Follow-up period, year (mean, median)**                                                                    2.01(0.87)     3.79(2.54)     \<0.0001[^‡^](#t001fn002){ref-type="table-fn"}           
  **Interval between onset of Parkinson\'s disease and the first CHM consultation, days mean (median)**                                      345.48(168.5)                                            

Abbreviate: CHM, Chinese herb medicine; DM, diabetes mellitus; AF, artial fibrillation; TIA, transient ischemic attack; CHF, congestive heart failure; PVD, peripheral vascular disease; SD, standard deviation.

‡ t test

^\#^ Chi-square test

† Fisher exact test.

§Drug included Pramipexole, Ropinirole, Rotigotine, Trihexyphenidyl, Levodopa, Entacapone, Rasagiline, Aspirin, and Plavix.

In Kaplan-Meier analysis, the cumulative incidence curve for stroke was significantly lower in the CHM users than in the non-CHM users (log-rank test P \<0.001) ([Fig 2](#pone.0203473.g002){ref-type="fig"}). PD patients using CHM had a 40% lower risk of stroke compared with PD patients who did not use CHM (unadjusted model, HR: 0.6; 95% CI: 0.47 to 0.77; P \<0.001). This beneficial effect was only slightly modified after adjusting for sociodemographic factors and comorbid conditions (adjusted HR \[aHR\]: 0.59; 95% CI: 0.46 to 0.76; P \<0.001) ([Table 2](#pone.0203473.t002){ref-type="table"}). Besides, compared with patients in the 18--59-year age group, those who aged between 60 and 69 years had a higher risk of stroke (aHR: 3.91; 95% CI: 1.92 to 7.95; P \<0.001) as did those who aged over 70 years (aHR: 4.76; 95% CI: 2.4 to 9.42; P \<0.001). Patients with hypertension also had a higher risk of stroke (aHR: 1.61; 95% CI: 1.21 to 2.15; P = 0.0011). Patients prescribed with anti-parkinsonian drugs had a lower risk of stroke (aHR: 0.61; 95% CI: 0.46 to 0.82; P = 0.0012) ([Table 2](#pone.0203473.t002){ref-type="table"}).

![The estimated cumulative incidence of stroke between the Chinese herb medicine (CHM) users and non-CHM users cohort among Parkinson's disease patients by Kaplan-Meier analysis.](pone.0203473.g002){#pone.0203473.g002}

10.1371/journal.pone.0203473.t002

###### Cox model measured hazard ratio and 95% confidence intervals of new-onset stroke in Parkinson\'s disease patients.

![](pone.0203473.t002){#pone.0203473.t002g}

  -----------------------------------------------------------------------------------------------------------------------------------------
  Variable                                              Stroke\         Crude   Adjusted                                         
                                                        no. (n = 257)                                                            
  ----------------------------------------------------- --------------- ------- --------------- ---------- ------ -------------- ----------
  **CHM used**                                                                                                                   

      Non-TCM users                                     135             1.00    reference                  1.00   reference      

      TCM users                                         122             0.60    (0.47--0.77)    \<0.0001   0.59   (0.46--0.76)   \< .0001

  **Sex**                                                                                                                        

      Female                                            120             1.00    reference                  1.00   reference      

      Male                                              137             0.95    (0.75--1.22)    0.7063     0.98   (0.76--1.26)   0.8529

  **Age, years**                                                                                                                 

      18--59                                            9               1.00    reference                  1.00   reference      

      60--69                                            59              4.42    (2.19--8.91)    \<0.0001   3.91   (1.92--7.95)   0.0002

      Older than 70 years                               189             5.62    (2.88--10.98)   \<0.0001   4.76   (2.41--9.42)   \< .0001

  **Baseline comorbidity**                                                                                                       

      Hypertension                                      181             1.89    (1.45--2.47)    \<0.0001   1.61   (1.21--2.15)   0.0011

      Hyperlipidemia                                    72              0.96    (0.73--1.27)    0.7923     0.83   (0.61--1.13)   0.234

      DM                                                77              1.06    (0.81--1.38)    0.693      1.00   (0.75--1.34)   0.9942

      AF                                                5               1.16    (0.48--2.81)    0.7469     0.91   (0.36--2.3)    0.8502

      CHF                                               15              1.17    (0.70--1.98)    0.5465     1      (0.58--1.74)   0.9902

      PVD                                               6               1.51    (0.67--3.40)    0.3175     1.25   (0.55--2.82)   0.5973

  **Drug used**[^§^](#t002fn003){ref-type="table-fn"}                                                                            

      No                                                61              1.00    reference                  1.00   reference      

      Yes                                               196             0.54    (0.41--0.72)    \< .0001   0.61   (0.46--0.82)   0.0012
  -----------------------------------------------------------------------------------------------------------------------------------------

Adjusted HR: Adjusted for CHM used, age, sex, baseline comorbidity and drug used in Cox proportional hazards regression.

Abbreviation: HR, hazard ratio; CI, confidence interval; CHM, Chinese herb medicine; DM, diabetes mellitus; AF, artial fibrillation; CHF, congestive heart failure; PVD, peripheral vascular disease.

§ Drug included Pramipexole, Ropinirole, Rotigotine, Trihexyphenidyl, Levodopa, Entacapone, Rasagiline, Aspirin, and Plavix.

We then explored the association between CHM prescription and stroke in analyses stratified by age, sex, comorbidities and medication use ([Table 3](#pone.0203473.t003){ref-type="table"}). Overall, the incidence rates of stroke for CHM users and non-CHM users were 11.10 per 100 person-years and 23.15 per 100 person-years, respectively. Compared with non-CHM user, using CHM was associated with a significantly lower risk of stroke among both females (aHR: 0.62; 95% CI, 00.42 to 0.91; P \<0.05) and males (aHR: 0.54; 95% CI: 0.38 to 0.77, P \<0.001); patients aged over 70 years (aHR 00.56; 95% CI, 0.42 to 0.76; P \<0.001); patients with hypertension (aHR: 0.53; 95% CI: 0.39 to 0.72; P \<0.001); patients without hyperlipidemia (aHR: 0.519; 95% CI: 0.37 to 0.68; P \<0.001), DM (aHR: 0.57; 95% CI: 0.42 to 0.77; P \<0.001), AF (aHR: 0.60; 95% CI: 0.46 to 0.77; P \<0.001), CHF (aHR: 0.56; 95% CI: 0.43 to 0.72; P \<0.001), and PVD (aHR: 0.58; 95% CI: 0.45 to 0.75; P \<0.001); and in those who did not use PD-related medications (aHR: 0.52; 95% CI: 0.29 to0.93; P \<0.01) as well as those who did (aHR: 0.58; 95% CI: 0.43 to 0.78; P \<0.001). However, using CHM was associated with significantly higher risk of stroke than non-CHM user when patient have CHF (aHR: 16.2; 95% CI: 2.11 to 124.33, P \<0.01).

10.1371/journal.pone.0203473.t003

###### Incidence rates, hazard ratio and confidence intervals of disorders of stroke association with and without CHM usage among Parkinson\'s disease patients in the stratification of sex, age, comorbidity and drug used.

![](pone.0203473.t003){#pone.0203473.t003g}

  Variables                                             CHM used   Compared with non-CHM users                                                                                              
  ----------------------------------------------------- ---------- ----------------------------- -------- ----- ------ -------- ----------------------------------------------------------- -----------------------------------------------------------
  **Total**                                             135        583                           231.54   122   1099   111.01   0.60(0.47--0.77)[\*\*\*](#t003fn007){ref-type="table-fn"}   0.59(0.46--0.76)[\*\*\*](#t003fn007){ref-type="table-fn"}
  **Sex**                                                                                                                                                                                   
      Female                                            60         290                           206.75   60    496    121.01   0.69(0.48--0.99)[\*](#t003fn005){ref-type="table-fn"}       0.62(0.42--0.91)[\*](#t003fn005){ref-type="table-fn"}
      Male                                              75         293                           256.11   62    603    102.79   0.52(0.37--0.74)[\*\*\*](#t003fn007){ref-type="table-fn"}   0.54(0.38--0.77)[\*\*\*](#t003fn007){ref-type="table-fn"}
  **Age, years**                                                                                                                                                                            
      18--59                                            6          138                           43.41    3     169    17.76    0.44(0.11--1.76)                                            0.69(0.15--3.13)
      60--69                                            30         155                           193.74   29    269    107.97   0.68(0.41--1.15)                                            0.65(0.38--1.13)
      Older than 70                                     99         290                           341.39   90    662    136.05   0.53(0.40--0.71)[\*\*\*](#t003fn007){ref-type="table-fn"}   0.56(0.42--0.76)[\*\*\*](#t003fn007){ref-type="table-fn"}
  **Baseline comorbidity**                                                                                                                                                                  
      Hypertension                                                                                                                                                                          
          No                                            37         290                           127.42   39    491    79.49    0.75(0.48--1.18)                                            0.76(0.48--1.23)
          Yes                                           98         293                           334.85   83    608    136.42   0.53(0.39--0.71)[\*\*\*](#t003fn007){ref-type="table-fn"}   0.53(0.39--0.72)[\*\*\*](#t003fn007){ref-type="table-fn"}
      Hyperlipidemia                                                                                                                                                                        
          No                                            109        438                           248.93   76    759    100.16   0.53(0.39--0.71)[\*\*\*](#t003fn007){ref-type="table-fn"}   0.51(0.37--0.68)[\*\*\*](#t003fn007){ref-type="table-fn"}
          Yes                                           26         145                           179.09   46    340    135.21   0.8(0.49--1.29)                                             0.92(0.54--1.57)
      DM                                                                                                                                                                                    
          No                                            99         455                           217.42   81    749    108.19   0.60(0.45--0.81)[\*\*\*](#t003fn007){ref-type="table-fn"}   0.57(0.42--0.77)[\*\*\*](#t003fn007){ref-type="table-fn"}
          Yes                                           36         128                           281.87   41    350    117.04   0.59(0.37--0.93)[\*](#t003fn005){ref-type="table-fn"}       0.63(0.39--1.01)
      AF                                                                                                                                                                                    
          No                                            131        575                           227.67   121   1082   111.84   0.61(0.48--0.78)[\*\*\*](#t003fn007){ref-type="table-fn"}   0.6(0.46--0.77)[\*\*\*](#t003fn007){ref-type="table-fn"}
          Yes                                           4          8                             521.79   1     17     58.33    0.23(0.03--2.14)                                            \-
      CHF                                                                                                                                                                                   
          No                                            129        544                           236.96   113   1068   105.84   0.56(0.44--0.73)[\*\*\*](#t003fn007){ref-type="table-fn"}   0.56(0.43--0.72)[\*\*\*](#t003fn007){ref-type="table-fn"}
          Yes                                           6          39                            155.19   9     31     287.15   1.87(0.66--5.26)                                            16.2(2.11--124.33)[\*\*](#t003fn006){ref-type="table-fn"}
      PVD                                                                                                                                                                                   
          No                                            133        576                           230.78   118   1086   108.67   0.59(0.46--0.76)[\*\*\*](#t003fn007){ref-type="table-fn"}   0.58(0.45--0.75)[\*\*\*](#t003fn007){ref-type="table-fn"}
          Yes                                           2          7                             296.23   4     13     304      1.12(0.12--10.33)                                           \-
  **Drug used**[^§^](#t003fn004){ref-type="table-fn"}                                                                                                                                       
      No                                                48         119                           404.84   34    259    131.29   0.50(0.32--0.79)[\*\*](#t003fn006){ref-type="table-fn"}     0.51(0.33--0.81)[\*\*](#t003fn006){ref-type="table-fn"}
      Yes                                               87         464                           187.3    88    840    104.76   0.65(0.48--0.88)[\*\*](#t003fn006){ref-type="table-fn"}     0.59(0.44--0.80)[\*\*\*](#t003fn007){ref-type="table-fn"}

Adjusted HR: adjusted for CHM used, age, sex, baseline comorbidity and drug used in Cox proportional hazards regression.

Reference group was non-CHM users.

Abbreviation: IR, incidence rates, per 1,000 person-years; HR, hazard ratio; CI, confidence interval; CHM, Chinese herb medicine; DM, diabetes mellitus.

§ Drug included Pramipexole, Ropinirole, Rotigotine, Trihexyphenidyl, Levodopa, Entacapone, Rasagiline, Aspirin, and Plavix.

\*:\< 0.05

\*\*:\< 0.01

\*\*\* p\<0.001

[Table 4](#pone.0203473.t004){ref-type="table"} compares medical expenditures for hospitalization and outpatient care between CHM users and non-CHM users over the first 3 months, 3 years and 5 years. Except mean medical expenditure of outpatients care was higher in over five years, in all three periods the medical expenditure was lower (but not significantly) among CHM users compared with non-CHM users.

10.1371/journal.pone.0203473.t004

###### Medical expenditure of hospitalization and outpatient care between CHM and non-CHM users for the first six months, 3years and 5years after incident Parkinson\'s disease.
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  Cost                       Non-CHM users   CHM users        P-value[^§^](#t004fn002){ref-type="table-fn"}                    
  -------------------------- --------------- ---------------- ----------------------------------------------- ---------------- --------
  **First 3 month**                                                                                                            
      Outpatients care, NT   283             17159(24955)     289                                             14372(15246)     0.1085
      Hospitalization, NT    74              149143(363738)   46                                              69764(136141)    0.093
  **First 3 years**                                                                                                            
      Outpatients care, NT   288             132047(201875)   290                                             130763(95079)    0.9222
      Hospitalization, NT    193             284805(560630)   160                                             215760(337874)   0.1546
  **First 5 years**                                                                                                            
      Outpatients care, NT   288             182836(283977)   290                                             191529(138882)   0.6407
      Hospitalization, NT    213             353634(681285)   194                                             258495(405785)   0.0847

Abbreviation: CHM, Chinese herb medicine; SD, standard deviation.

§ t-test.

Finally, we analyzed prescription patterns of Chinese herbs issued by TCM doctors. Many CHM in single herbal preparations or in formulas of multiple herbs have been prescribed for CHM users. The two most commonly used single herbal preparations consisted of Danshen and Rhubarb; the two most common herbal formulas were Ma Zi Ren Wan and Du Huo Ji Sheng Tang. The average prescription duration of ten most commonly used single herbal preparations and herbal formulas were 7.53 days and 8.12 days, respectively ([Table 5](#pone.0203473.t005){ref-type="table"}). There is no significant correlation between the daily CHM dosage and the risk of stroke ([Table 6](#pone.0203473.t006){ref-type="table"}).

10.1371/journal.pone.0203473.t005

###### Ten most common single herbs and herbal formulas prescribed.
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                              Frequency   Number of person-days   Average daily dose (g)   Average duration for prescription (days)
  --------------------------- ----------- ----------------------- ------------------------ ------------------------------------------
  **Single herb**                                                                          
      Danshen                 188         1363                    6.1                      7.3
      Rhubarb                 159         1242                    0.8                      7.8
      Gouteng                 150         1459                    1.3                      9.7
      Huangqi                 105         768                     1.4                      7.3
      Ophiopogon              103         725                     2.6                      7
      Millettia               102         828                     4.2                      8.1
      Magnolia                102         711                     1                        7
      Lotus seeds             92          638                     2.6                      6.9
      Licorice                90          615                     1.2                      6.8
      Danggui                 89          659                     1.3                      7.4
  **Herb formula**                                                                         
      Ma Zi Ren Wan           258         2849                    7                        11
      Du Huo Ji Sheng Tang.   215         1591                    8.6                      7.4
      Shujing Huoxue Tang     162         1231                    4.5                      7.6
      Ganmai jujube soup      145         1078                    4                        7.4
      Suanzaoren soup         131         981                     5.8                      7.5
      Liu Wei Di Huang Wan    117         799                     4                        6.8
      Jia Weixiao yao san     117         1065                    3.7                      9.1
      Tian Wang Bu Xin Dan    108         996                     4                        9.2
      Shao Yao Gan Cao Tang   103         827                     4                        8
      Bu Yang Huan Wu Tang    93          665                     10                       7.2

10.1371/journal.pone.0203473.t006

###### Hazard Ratios and confidence intervals of stroke risk associated with average dosage per day of CMH.
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  Dosage of CMH/per day     N     No. of event   Crude HR           Adjusted HR
  ------------------------- ----- -------------- ------------------ ------------------
  **Chinese herb users**                                            
      Less than 12.68 (g)   72    32             1(reference)       1(reference)
      12.68--14.23 (g)      71    32             0.99(0.61--1.62)   1.06(0.64--1.75)
      More than 14.23 (g)   147   58             0.97(0.63--1.50)   1.06(0.68--1.66)

Adjusted HR: adjusted for CHM used, age, sex, baseline comorbidity and drug used in Cox proportional hazards regression.

Abbreviation: HR, hazard ratio; CI, confidence interval; CHM, Chinese herb medicine; DM, diabetes mellitus.

Discussion {#sec008}
==========

In the present study, we evaluated whether CHM treatment reduced the risk of stroke among PD patients using a Longitudinal Health Insurance Database in Taiwan. Of all 1,882 PD patients who were included in this study, almost half (N = 853; 45%) had ever took CHM. After controlling several potential confounding factors, the CHM users among patients with PD revealed a significant decrease in risk of new-onset stroke than matched non-CHM users, expect the patients with CHF. Among these CHM users, the most commonly used single herb is Danshen and the most common herbal formula is Ma Zi Ren Wan.

In our multivariable Cox proportional hazard analysis, the risk of stroke after PD diagnosis was significantly reduced among CHM users compared with non-CHM users. After adjusted for residual confounding effects, the CHM users still have significant lower risk than non-CHM users even in the subgroup with higher risk of stroke (i.e. PD patient who aged over 70 years and who with hypertension). The reduction of the risk may be benefit by the prevention effect of the CHM on cardiovascular disease. Although the underlying mechanisms are not fully explored, recent studies suggest that the prevention and treatment role of CHM on cardiovascular diseases may achieved via the mechanism of antioxidants, anti-inflammation, and anti-apoptosis \[[@pone.0203473.ref020]\]. Our analysis on the prescription patterns of CHM further support the notion of the prevention effect of the CHM on cardiovascular disease. Danshen, the dried root of *Salvia miltiorrhiza*, is used to promote blood flow and treat vascular disease \[[@pone.0203473.ref021]\]. Its pharmacologic mode of action may help to prevent the development of atherosclerosis and it may also have antihypertensive and anti-platelet aggregation effects, helping to prevent cerebral infarction \[[@pone.0203473.ref022]\]. The formula Du Huo Ji Sheng Tang effectively attenuates inflammation and promotes lymphatic drainage in the TNF-α-transgenic mouse model of rheumatoid arthritis (RA) \[[@pone.0203473.ref013]\]. Du Huo Ji Sheng Tang has long been used in China to treat patients with osteoarthritis and is well-recognized for its ability to improve patients' clinical symptoms and knee function \[[@pone.0203473.ref023]\]. Hence, the prevention effect of the CHM on new-onset stroke in PD patients may be achieved through the mechanisms of antioxidants, anti-inflammation, and anti-apoptosis.

The alternative explanation for the prevention effect of the CHM might be the life style of the PD patients. A nationwide survey conducted in Taiwan during 2002 and 2003 revealed that people who exercised regularly were more likely to use TCM services than people who did not exercise regularly \[[@pone.0203473.ref024]\]. In comparison to patients with PD who do choose not to use TCM, those who do may have more positive attitudes towards physical rehabilitation and disease prevention, which may contribute to the reduction of new-onset stroke events after PD diagnosis. However, the same survey also revealed that people with self-reported poor health status are more likely to use TCM services than people who consider they have very good health status \[[@pone.0203473.ref024]\], indicating that TCM users have more comorbidities than their healthier counterparts and therefore require more healthcare. In the present study, a significantly higher proportion of CHM users compared with non-CHM users had hyperlipidemia, which is known to increase the risk of stroke secondary to atherosclerosis \[[@pone.0203473.ref025]\], indicating a poor health state in CHM users. Although there appeared to be no such association for the occurrence of stroke in our study, there is no significant difference between CHM and non-CHM users on the risk of stroke in the PD patients with hyperlipidemia. Thus, the life style might be a minor factor to reduce the risk of ischemic stroke on PD patients.

An interesting finding in the present study is that the Ma Zi Ren Wan formula has been most common prescription of CHM on PD patients. The Ma Zi Ren Wan formula has been used for over two thousand years in China and other Asian countries to treat constipation \[[@pone.0203473.ref026]\]. A recent systematic review and meta-analysis of 9 studies involving a total of 741,593 participants reported that people with constipation were more than twice as likely (pooled odds ratio, 2.27; 95% CI, 2.09 to 2.46) to develop subsequent PD than those without constipation \[[@pone.0203473.ref027]\]. Thus, it raised a possibility that CHM may also have the prevention or treatment effect in PD \[[@pone.0203473.ref028]\]. Previous studies demonstrated that Chinese herb and herbal extracts have neuroprotective effect on dopaminergic neurons by the distinct mechanisms as antioxidants, free radical scavengers, and anti-apoptosis activity \[[@pone.0203473.ref029]\]. A recent, large, population-based follow-up study has reported a significantly increased risk of ischemic stroke among patients with PD compared with propensity score-matched subjects without PD, whereas the increased risk of ischemic stroke in PD patients may associated with the common risk factors between PD and ischemic stroke, e.g. oxidative stress, diabetes, and hypertension \[[@pone.0203473.ref011]\]. Hence, it is plausible that the mechanisms which underlying the prevention effect of CHM on stroke in PD patients may also contribute to the prevention or treatment effect of CHM in PD. However, there is no detailed patient information (e.g., lifestyles, physical, mental and laboratory examinations) in the LHID2010 database. Further randomized clinical trials are needed to clarify whether these CHM prescription help to prevent PD.

Notably, although there were too few samples for statistical significance, our study found that patients with PD who received CHM treatment were less costly to care for, whether they were outpatients or hospitalized, during the first 3 months to first 3 years after their PD diagnosis. Moreover, the cost of hospitalization care still less in CHM users than non-CHM users even 5 years after PD has been diagnosed. Since the hospitalization care mostly has been conducted for serious medical conditions, the lower cost of hospitalization care in CHM users may partly contributed by the lower risk of stroke in PD patient. On the other hand, the cost of outpatient care was less reduced than hospitalized care in CHM user, and even slightly higher in 5 years after PD has been diagnosed. These results may partly due to the combined cost from both outpatient department of TCM and western medicine, which may conceal the true reduction effect on medical expenditure from CHM prescription. Our findings are echoed by other Taiwanese researches reporting that TCM is associated with the lowest total expenditure per person-time when compared with Western medicine and integrated Chinese-Western medicine among people seeking treatment for allergic rhinitis \[[@pone.0203473.ref030]\] and that acupuncture treatment reduces use of emergency care and hospitalization in patients with traumatic brain injury \[[@pone.0203473.ref031]\].

The advantages of this study include the large sample size and use of claims data from the LHID2010, containing 1,000,000 random samples from all beneficiaries in the NHIRD in 2010. Furthermore, time-independent multivariate Cox proportional hazards analysis controlled for residual confounding bias. Study limitations include its use of retrospective medical claims data, which lack detailed patient information about lifestyles, physical, mental and laboratory examinations. Moreover, we used the ICD-9-CM code for PD, without any evidence as to the level of disease severity. As mentioned in the materials and methods, it is also very important to point out that the immortal time bias may exist in this cohort study because of the use of a time fixed analysis. Future prospective studies should include these variables to conquer these limitations.

Conclusions {#sec009}
===========

The results of this nationwide retrospective cohort study suggest that PD patients using CHM treatment are at lower risk of new-onset stroke compared with PD patients who do not use CHM treatment. The association between CHM treatment and decreased risk of stroke among PD patients existed for both females and males, and for all age groups. The use of CHM by patients with PD in Taiwan is common. Additional pharmacologic investigations or clinical trials could be conducted to further validate the efficacy of commonly prescribed CHM. Overall, our study provides valuable information and adds value to existing knowledge about healthcare for patients with PD, and may provide directions for the design of future therapeutic strategies.
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